NO994527L - 2,3-dihydrofuro[3,2-b]pyridin, dets fremstilling og anvendelse derav i terapi - Google Patents

2,3-dihydrofuro[3,2-b]pyridin, dets fremstilling og anvendelse derav i terapi

Info

Publication number
NO994527L
NO994527L NO994527A NO994527A NO994527L NO 994527 L NO994527 L NO 994527L NO 994527 A NO994527 A NO 994527A NO 994527 A NO994527 A NO 994527A NO 994527 L NO994527 L NO 994527L
Authority
NO
Norway
Prior art keywords
group
alkyl group
hydrogen atom
compounds
dihydrofuro
Prior art date
Application number
NO994527A
Other languages
English (en)
Other versions
NO994527D0 (no
Inventor
Alistair Lochead
Samir Jegham
Frederic Galli
Thierry Gallet
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of NO994527D0 publication Critical patent/NO994527D0/no
Publication of NO994527L publication Critical patent/NO994527L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Oppfinnelsen vedrører forbindelser med generell formel (I) hvor R-L representerer et hydrogenatom, en (C^-Cg) alkylgruppe eller en fenyl (C1-C4) alkylgruppe, R2 representerer et hydrogenatom eller en (C^-Cg)alkylgruppe, og R3, R4 og R5 representerer hver, uavhengig av hverandre, et hydrogenatom eller halogenatom eller en trifluormetylgruppe, cyanogruppe, hydroksygruppe, (C^-Cg)alkylgruppe eller (C^-Cg)alkoksygruppe. Resultatene av biologiske forsøk gjennomført på de nevnte forbindelser viser at de er kraftige og selektive kolinergiske ligander for nikotinreseptorer. Disse resultater foreslår at forbindelsene kan anvendes for å behandle eller forebygge lidelser som er relatert til dysfunksjon av nikotinreseptorer, særlig i sentralnerve- systemet eller i det gastrointestinale system.
NO994527A 1997-03-20 1999-09-17 2,3-dihydrofuro[3,2-b]pyridin, dets fremstilling og anvendelse derav i terapi NO994527L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9703395A FR2761072B1 (fr) 1997-03-20 1997-03-20 Derives de 2,3-dihydrofuro[3,2-b]pyridine, leur preparation et leur application en therapeutique
PCT/FR1998/000531 WO1998042713A1 (fr) 1997-03-20 1998-03-17 DERIVES DE 2,3-DIHYDROFURO[3,2-b]PYRIDINE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE

Publications (2)

Publication Number Publication Date
NO994527D0 NO994527D0 (no) 1999-09-17
NO994527L true NO994527L (no) 1999-11-18

Family

ID=9505006

Family Applications (1)

Application Number Title Priority Date Filing Date
NO994527A NO994527L (no) 1997-03-20 1999-09-17 2,3-dihydrofuro[3,2-b]pyridin, dets fremstilling og anvendelse derav i terapi

Country Status (22)

Country Link
US (1) US6143761A (no)
EP (1) EP0971929A1 (no)
JP (1) JP2001518099A (no)
KR (1) KR20000076282A (no)
CN (1) CN1251105A (no)
AR (1) AR012097A1 (no)
AU (1) AU6924298A (no)
BG (1) BG103684A (no)
BR (1) BR9808346A (no)
CA (1) CA2282320A1 (no)
CO (1) CO4940417A1 (no)
EE (1) EE9900414A (no)
FR (1) FR2761072B1 (no)
HU (1) HUP0002335A3 (no)
IL (1) IL131254A0 (no)
NO (1) NO994527L (no)
NZ (1) NZ337566A (no)
PL (1) PL335759A1 (no)
SK (1) SK127699A3 (no)
TR (1) TR199902115T2 (no)
WO (1) WO1998042713A1 (no)
ZA (1) ZA982365B (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2790474B1 (fr) 1999-03-05 2001-04-06 Synthelabo Derives de pyridopyranoazepines, leur preparation et leur application en therapeutique
SE9902267D0 (sv) * 1999-06-16 1999-06-16 Astra Ab New compounds
JP2005104838A (ja) * 2003-01-09 2005-04-21 Tanabe Seiyaku Co Ltd 縮合フラン化合物
US20070191815A1 (en) 2004-09-13 2007-08-16 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery
GB2448224B (en) 2007-04-02 2010-09-01 Parkinson S Inst Solid orally administered pharmaceutical composition for the reduction of side-effects of a dopaminergic agent
JP2018511355A (ja) 2015-01-28 2018-04-26 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 薬剤送達方法及びシステム
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
EP3565617A1 (en) 2017-01-06 2019-11-13 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
AU2019279884A1 (en) 2018-05-29 2020-12-10 Morningside Venture Investments Limited Drug delivery methods and systems

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0842178T3 (da) * 1995-07-28 2001-08-06 Abbott Lab Furopyridin, thienopyridin, pyrrolopyridin og beslægtede pyrimidin-, pyridazin- og triazinforbindelser, som er nyttige til regulering af kemisk synaptisk transmission

Also Published As

Publication number Publication date
IL131254A0 (en) 2001-01-28
ZA982365B (en) 1998-09-23
JP2001518099A (ja) 2001-10-09
FR2761072B1 (fr) 1999-04-23
NO994527D0 (no) 1999-09-17
PL335759A1 (en) 2000-05-22
TR199902115T2 (xx) 2000-01-21
BG103684A (en) 2000-06-30
SK127699A3 (en) 2000-05-16
AR012097A1 (es) 2000-09-27
US6143761A (en) 2000-11-07
NZ337566A (en) 2000-09-29
HUP0002335A2 (hu) 2001-05-28
BR9808346A (pt) 2000-05-23
AU6924298A (en) 1998-10-20
EE9900414A (et) 2000-04-17
EP0971929A1 (fr) 2000-01-19
FR2761072A1 (fr) 1998-09-25
WO1998042713A1 (fr) 1998-10-01
CO4940417A1 (es) 2000-07-24
CA2282320A1 (en) 1998-10-01
KR20000076282A (ko) 2000-12-26
HUP0002335A3 (en) 2002-07-29
CN1251105A (zh) 2000-04-19

Similar Documents

Publication Publication Date Title
GB9921150D0 (en) Therapeutic agents
HUP0301069A2 (hu) Új biaril-karboxamidok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
ES2000299A6 (es) Procedimiento para la preparaciom de nuevos derivados de n-aralquil-piperinmetanol
NO990304L (no) Substituerte triazol-pyridazolderivater som ligander for GABA reseptorer
MA30631B1 (fr) Inhibiteurs de tyrosine kinase
GB9927687D0 (en) Therapeutic agents
BG101806A (en) Indole derivatives as 5-ht receptor antagoniss
WO2002076946A3 (en) Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain.
DK1112106T3 (da) Serotonerge 5HT2-agonister til behandling af glaukom
NO20021356L (no) Alkylendiamin-substituerte pyrazolo[1,5,-a]-1,5-pyrimidiner og pyrazolo[1,5-a]-1,3,5-triaziner
EP0445811A3 (en) Nitrogen-containing heterocyclic compounds, their production and use
NO994527L (no) 2,3-dihydrofuro[3,2-b]pyridin, dets fremstilling og anvendelse derav i terapi
NO20010151L (no) N-substituerte naftalenkarboksamider som neurokininreseptorantagonister
DE60108639D1 (de) Aryl- und heteroaryldiazabicycloalkane, deren zubereitung und verwendung
UA66865C2 (uk) Інденопіролокарбазоли, фармацевтична композиція, спосіб інгібування кіназної активності та спосіб лікування (варіанти)
NO963731L (no) Behandling av obsessive-kompulsive sykdommer med 5HT2-antagonister
WO2002004455A3 (en) 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof
NO20080417L (no) Benzosykloheptapyridiner som inhibitorer av reseptortyrosinkinasen MET
CA2360754A1 (en) Use of pyridazino[4,5-b]indole-1-acetamide derivatives for preparing medicines for treating diseases related to the dysfunction of peripheral benzodiazepin receptors
MX9806171A (es) Derivados 2,3-benzodiazepina y sus usos como inhibidores del receptor-ampa.
DK1194415T3 (da) Nye piperazinylalkylthiopyrimidinderivater, farmaceutiske sammensætninger indeholdende disse samt en fremgangsmåde til deres fremstilling
NZ501417A (en) Crystalline polymorphs of descarbonylethoxyloratadine (8-chloro-6, 11-dihydro-11-(4-piperidylidene)-5H-benzo[5,6] cyclohepta[1,2-b]pyridine) and methods for their use
NO973342L (no) Anvendelse av 3,4-difenylkromaner til fremstilling av et farmasöytisk preparat for behandling eller profylakse av cerebrale degenerative sykdommer
NO308658B1 (no) Sammenføyde isoquinoliner som dopamin-reseptor-ligander
DE69726749D1 (de) 5-heteroatom-alkyl substituierte 3-oxo-pyrido(1,2-a)benzimidazol-4-carboxamid derivate zur behandlung zentral nervöser system störungen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application